Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Licht

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Cancer Discovery|July 25, 2019
A Mutation in Histone H2B Represents a New Class of Oncogenic DriverRichard L Bennett, Aditya Bele, Eliza C Small, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
KDM6A Regulates Immune Response Genes in Multiple MyelomaDaphne Dupéré-Richer, Alberto Riva, Sayantan Maji, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 23, 2022
Low muscle mass is associated with a higher risk of all-cause and cardiovascular disease-specific mortality in cancer survivorsDongyu Zhang, Kori A Spiropoulos, Akemi Wijayabahu, et al.
Blood|July 24, 2024
KDM6A regulates immune response genes in multiple myelomaDaphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, et al.
Blood|April 10, 2024
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenomeAmin Sobh, Elena Encinas, Alisha Patel, et al.
Cancer Cell|August 10, 2016
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and LymphomagenesisWendy Béguelin, Matt Teater, Micah D Gearhart, et al.
Oncogene|January 26, 2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancerDamiano Fantini, Alexander P Glaser, Kalen J Rimar, et al.
Journal of the American Chemical Society|March 28, 2023
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2Ronan P Hanley, David Y Nie, John R Tabor, et al.
Plos Genetics|September 5, 2014
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationRelja Popovic, Eva Martinez-Garcia, Eugenia G Giannopoulou, et al.
Cancer Discovery|August 21, 2021
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic LeukemiaJianping Li, Julia Hlavka-Zhang, Jonathan H Shrimp, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Cancer Discovery|July 25, 2019
A Mutation in Histone H2B Represents a New Class of Oncogenic DriverRichard L Bennett, Aditya Bele, Eliza C Small, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
KDM6A Regulates Immune Response Genes in Multiple MyelomaDaphne Dupéré-Richer, Alberto Riva, Sayantan Maji, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 23, 2022
Low muscle mass is associated with a higher risk of all-cause and cardiovascular disease-specific mortality in cancer survivorsDongyu Zhang, Kori A Spiropoulos, Akemi Wijayabahu, et al.
Blood|July 24, 2024
KDM6A regulates immune response genes in multiple myelomaDaphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, et al.
Blood|April 10, 2024
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenomeAmin Sobh, Elena Encinas, Alisha Patel, et al.
Cancer Cell|August 10, 2016
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and LymphomagenesisWendy Béguelin, Matt Teater, Micah D Gearhart, et al.
Oncogene|January 26, 2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancerDamiano Fantini, Alexander P Glaser, Kalen J Rimar, et al.
Journal of the American Chemical Society|March 28, 2023
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2Ronan P Hanley, David Y Nie, John R Tabor, et al.
Plos Genetics|September 5, 2014
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylationRelja Popovic, Eva Martinez-Garcia, Eugenia G Giannopoulou, et al.
Cancer Discovery|August 21, 2021
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic LeukemiaJianping Li, Julia Hlavka-Zhang, Jonathan H Shrimp, et al.
Pageof 18